Related Experiment Video

Updated: Jun 20, 2026

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition
04:53

A Clinical Trial Assessing the Safety, Efficacy, and Delivery of Olive-Oil-Based Three-Chamber Bags for Parenteral Nutrition

Published on: September 20, 2019

The pediatric hydroxyurea phase III clinical trial (BABY HUG): challenges of study design

Bruce W Thompson1, Scott T Miller, Zora R Rogers

  • 1Clinical Trials & Surveys Corp., Baltimore, Maryland 21117, USA. bthompson@c-tasc.com

Pediatric Blood & Cancer
|September 5, 2009
PubMed

Insights

Hydroxyurea treatment in infants with sickle cell anemia may prevent organ damage. The BABY HUG trial investigated hydroxyurea

Area of Science:

  • Pediatric Hematology
  • Clinical Pharmacology
  • Sickle Cell Disease Research

Background:

  • Hydroxyurea has demonstrated benefits in adults and children with sickle cell anemia, primarily by reducing vaso-occlusive events.
  • A need exists for definitive clinical trials to confirm hydroxyurea's efficacy in preventing organ damage, supporting its early-age use.

Purpose of the Study:

  • To evaluate the efficacy of hydroxyurea in preventing organ damage, specifically in the kidneys and spleen, in young children with sickle cell anemia.
  • To assess if daily hydroxyurea treatment for two years can decrease organ damage by at least 50% in infants aged 9-17 months.

Main Methods:

  • The BABY HUG trial is a randomized, double-blind, placebo-controlled study.
  • Participants (n=200) received either liquid hydroxyurea (20 mg/kg/day) or a placebo for two years.
  • Organ damage in kidneys and spleen was the primary endpoint, with safety monitoring and blinding procedures in place.

Main Results:

  • This abstract does not contain specific results, but outlines the study design and endpoints.
  • The study was designed to detect a 50% reduction in organ damage.
  • Safety and feasibility were assessed in a prior pilot study.

Conclusions:

  • The BABY HUG trial aimed to provide crucial evidence for the early use of hydroxyurea to prevent long-term complications in children with sickle cell anemia.
  • Preservation of spleen and renal function are clinically relevant endpoints for this vulnerable population.
  • The study design addressed challenges related to subject recruitment, safety monitoring, and maintaining study integrity.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...